Compare Novartis AG (NVS) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Real Estate Index Fund ETF — how do they compare? Novartis AG trades at $143.31 (market cap $268.57B), while Vanguard Real Estate Index Fund ETF trades at $90.43 (market cap $70.80B). The key difference: Novartis AG is far larger — about 3.8× Vanguard Real Estate Index Fund ETF's market cap, and Novartis AG pays a 3.31% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vanguard Real Estate Index Fund ETF for 112 Days on average.
| NVS | VNQ | |
|---|---|---|
Market Cap | $268.57B | $70.80B |
Volume | 1,532,573 | 6,073,580 |
Sector | Health | — |
52-Week High | $168.62 | $100.95 |
52-Week Low | $121.80 | $87.00 |
Typical Hold Time | 82 Days | 112 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VNQ trades at $90.02, up 1.5% today amid a bearish technical trend. The ETF faces pressure from rising Treasury yields, with moving averages signaling sell conditions. Recent news highlights institutional buying despite sector headwinds, as REITs grapple with interest rate sensitivity and valuation concerns. The dividend yield remains a focal point, though competition from T-bills challenges its income appeal.
Outlook: Near-term risks from Fed policy and sector rotation persist, but contrarian opportunities exist for long-term investors. Key risks include interest rate volatility and economic slowdowns, while potential upside hinges on rate stabilization and real estate demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
